SIS Innovation

A novel, non-toxic, the short peptide has been isolated from snake venom based on its highly potent in-vivo analgesic activity upon topical application. A whole family of related compounds has been identified in various snake venoms based on this novel molecule. One of the naturally occurring peptides (coded ZEP-4) and its chemically modified version (coded ZEP-3) were chemically synthesized in kilogram quantities.

Unique advantages

Shulov Innovative Science is an advanced clinical-stage biopharmaceutical company focused on the development and commercialization of New Chemical Entities (NCE’s) for topical drug products.
SIS is developing several ‘NCE’s for anti-inflammatory indications. ZEP-3 possess a unique, combination of pharmacological activities for the treatment of these clinical areas of research. The unique combination of anti-inflammatory and anti-viral activity, in addition to analgesic activity, gives ZEP-3 an advantage over the existing treatments for Herpes Labialis (“HL” or cold sores), which are only based on anti-viral activity (Zovirax).
In addition, Efficacy studies have shown that ZEP-3 is equally effective both on HSV-1 and HSV-2 for acyclovir-resistant viruses. At the same time, a growing population does not respond to the existing therapy because of acyclovir resistance.
Regarding Atopic Dermatitis, the company has significant competitive advantages in the Atopic Dermatitis field (AD). The AD treatments available today mainly use steroid drugs which often involve the risk of side effects, especially when administered to children. The Company’s ZEP-3 is not based on steroids, thus giving the company a clear and unique advantage over other competitors in this indication.
An additional indication SIS is targeting is Burns. Using a pig model, the results show that ZEP-3 cream improved the time and scope of healing burns.
Lung Inflammation: ZEP-3 effectively reduces lung inflammation by reducing the presence of Eosinophils, Neutrophils, and G-CSF in the lung fluids by Intratracheal (IT administration) and by inhalation, thus leading to a significant reduction of MIP-1α and IL-10.